World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025

D-Index & Metrics

Best Scientists

D-Index
206
Citations
212225
World Ranking
231
National Ranking
154

Medicine

D-Index
210
Citations
224677
World Ranking
133
National Ranking
90

Research.com Recognitions

  • 2025 - Research.com Best Scientists Award

Overview

José Baselga was affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focused on biochemistry, genetics, and molecular biology, with significant contributions in molecular biology, cancer research, oncology, pulmonary and respiratory medicine, and cell biology.

Their work covered various main topics including cancer-related gene regulation, histone deacetylase inhibitors research, protein degradation and inhibitors, microRNA in disease regulation, cancer-related molecular mechanisms research, cancer cells and metastasis, and advanced breast cancer therapies.

  • Cancer-related gene regulation
  • Histone Deacetylase Inhibitors Research
  • Protein Degradation and Inhibitors
  • MicroRNA in disease regulation
  • Cancer-related molecular mechanisms research
  • Cancer Cells and Metastasis
  • Advanced Breast Cancer Therapies

Frequent coauthors in their research included Eneda Toska, Patrizia Mondello, Saber Tadros, Matt Teater, and Lorena Fontán.

  • Eneda Toska
  • Patrizia Mondello
  • Saber Tadros
  • Matt Teater
  • Lorena Fontán

Their research outputs were published in several journals, with frequent publication venues being Cancer Discovery, International Journal of Molecular Sciences, Cancer Research, and Clinical Cancer Research.

  • Cancer Discovery
  • International Journal of Molecular Sciences
  • Cancer Research
  • Clinical Cancer Research

Notable recent papers included:

  • Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma, 2020, Cancer Discovery
  • Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy, 2020, International Journal of Molecular Sciences
  • Abstract P3-03-01: Double PIK3CA mutations in cis drive oncogene addiction and enhance sensitivity to PI3K alpha inhibitors in breast cancer, 2020, Cancer Research
  • Editor's Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and Prognosis, 2024, Clinical Cancer Research

Best Publications

  • Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

    Dennis J. Slamon;Brian Leyland-Jones;Steven Shak;Hank Fuchs

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

    James A. Bonner;Paul M. Harari;Jordi Giralt;Nozar Azarnia

  • The landscape of somatic copy-number alteration across human cancers

    Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

    Sunil Verma;David Miles;Luca Gianni;Ian E. Krop

  • Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

    Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura

  • Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    José Baselga;Mario Campone;Martine Piccart;Howard A. Burris

  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

    Ahmet Zehir;Ryma Benayed;Ronak H Shah;Aijazuddin Syed

  • mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

    Kathryn E. O'Reilly;Fredi Rojo;Qing Bai She;David Solit

  • Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

    José Baselga;Javier Cortés;Sung-Bae Kim;Seock-Ah Im

  • Systematic identification of genomic markers of drug sensitivity in cancer cells

    Mathew J. Garnett;Elena J. Edelman;Sonja J. Heidorn;Christopher Greenman;Christopher Greenman

  • Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

    Min Yu;Aditya Bardia;Ben S. Wittner;Shannon L. Stott

  • Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

    James A Bonner;Paul M Harari;Jordi Giralt;Roger B Cohen

  • Genomic analysis identifies association of Fusobacterium with colorectal carcinoma

    Aleksandar D. Kostic;Dirk Gevers;Chandra Sekhar Pedamallu;Chandra Sekhar Pedamallu;Monia Michaud

  • Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

    Sandra M. Swain;José Baselga;Sung-Bae Kim;Jungsil Ro

  • OncoKB: A Precision Oncology Knowledge Base.

    Debyani Chakravarty;Jianjiong Gao;Sarah Phillips;Ritika Kundra

  • Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

    J. Baselga;Debasish Tripathy;J. Mendelsohn;S. Baughman

  • A view on drug resistance in cancer

    Neil Vasan;Neil Vasan;José Baselga;José Baselga;José Baselga;David M. Hyman;David M. Hyman

Frequent Co-Authors

Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
David M. Hyman
David M. Hyman Memorial Sloan Kettering Cancer Center
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Sarat Chandarlapaty
Sarat Chandarlapaty Memorial Sloan Kettering Cancer Center
Martine Piccart
Martine Piccart Université Libre de Bruxelles
David B. Solit
David B. Solit Memorial Sloan Kettering Cancer Center
Joaquín Arribas
Joaquín Arribas Institució Catalana de Recerca i Estudis Avançats
Evandro de Azambuja
Evandro de Azambuja Université Libre de Bruxelles
Hope S. Rugo
Hope S. Rugo University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees can open doors to rewarding roles within the healthcare field, even beyond traditional medical education. Many students begin by gaining practical experience and certifications through specialized programs. For example, enrolling in the best online medical billing and coding schools can qualify you for in-demand administrative roles, with programs often accessible and offering financial aid.

Nursing is another popular pathway. Interestingly, do all nursing schools require the teas exam? Not necessarily—some accredited nursing schools do not require the TEAS or HESI exams for admission, providing more flexibility for prospective students.

For those looking to lead within healthcare organizations, pursuing a healthcare administration degree online accredited can accelerate career advancement, offering the convenience of fully online study. Registered nurses seeking further advancement can benefit from asn to np programs, which enable a seamless transition from an associate degree in nursing to advanced nurse practitioner credentials.

Best Scientists Citing José Baselga

Recently Published Articles